Anti-CD38-targeted IGG4-attenuated IFNA TAK-573
Anti-CD38-targeted IGG4-attenuated IFNA TAK-573 Uses, Dosage, Side Effects, Food Interaction and all others data.
Anti-CD38-targeted IGG4-attenuated IFNA TAK-573 is under investigation in clinical trial NCT03215030 (A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM)).
| Trade Name | Anti-CD38-targeted IGG4-attenuated IFNA TAK-573 |
| Generic | Modakafusp alfa |
| Modakafusp alfa Other Names | Anti-CD38-targeted IGG4-attenuated IFNA TAK-573, Modakafusp alfa |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Anti-CD38-targeted IGG4-attenuated IFNA TAK-573
